Skip to content

Anti-histamines and Methacholine Challenges.

The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01985789
Enrollment
12
Registered
2013-11-15
Start date
2013-11-30
Completion date
2014-05-31
Last updated
2015-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

airway hyperresponsiveness

Brief summary

The asthmatic airway is identified and studied using inhaled agents such as histamine and methacholine. The use of antihistamines prior to the test will inhibit the test result if histamine is used to cause airway constriction. If using methacholine, this may also be true depending on whether old (e.g. benadryl) or new (e.g. desloratadine) antihistamines are used. This study will look at the effect of old and new antihistamines on inhaled methacholine challenge response in individuals with mild asthma.

Interventions

DRUGDiphenhydramine
DRUGcetirizine
DRUGdesloratadine
DRUGplacebo

Sponsors

Don Cockcroft
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Baseline forced expiratory volume in 1s (FEV1) of 70% or more of predicted * Methacholine provocative concentration causing a 20% fall in FEV1 16mg/ml or less * No respiratory infection or change in allergen exposure for 4 weeks prior to screening and throughout the study * No significant medical co-morbidities * allergy

Exclusion criteria

* pregnant or breastfeeding females * unable to withhold antihistamines, anticholinergics, long acting bronchodilators and combination therapies

Design outcomes

Primary

MeasureTime frame
change in methacholine pc20change from baseline (pre dose) at 2 hours (post dose)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026